This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-21. Anything still debated is marked as such rather than presented as settled.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
=== Acidic pH inactivation === Some viruses, when exposed to a low pH, will denature spontaneously. Similar to pasteurization, this technique for viral inactivation is useful if the target protein is more resistant to low pHs than the viral impurity. This technique is effective against enveloped viruses, and the equipment typically used is simple and easy to operate. This type of inactivation method is not as effective for non-enveloped viruses however, and also requires elevated temperatures. So in order to use this method, the target protein must be resistant to low pHs and high temperatures which is unfortunately not the case for many biological proteins. Incubation for this process typically occurs at a pH of 4 and lasts anywhere between 6 hours and 21 days. Acidic inactivation is commonly used in the manufacturing process for monoclonal antibody based biopharmaceuticals. The process consists of reducing the pH to near or below a pH of 3.6 and incubation for at least thirty minutes at room temperature.
=== Hypnotic === Chloral hydrate has not been approved by the FDA in the United States nor the EMA in the European Union for any medical indication and is on the FDA list of unapproved drugs that are still prescribed by clinicians. Usage of the drug as a sedative or hypnotic may carry some risk given the lack of clinical trials. However, chloral hydrate products, licensed for short-term management of severe insomnia, are available in the United Kingdom. Chloral hydrate was voluntarily removed from the market by all manufacturers in the United States in 2012. Prior to that, chloral hydrate may have been sold as a "legacy" or "grandfathered" drug; that is, a drug that existed prior to the time certain FDA regulations took effect and therefore, some pharmaceutical companies have argued, has never required FDA approval. New drugs did not have to be approved for safety until Congress passed the Federal Food, Drug, and Cosmetic Act (the "FD&C Act") in 1938. Further, a new drug did not have to be proven effective until 1962, when Congress amended the Act. Manufacturers contend that such "legacy drugs", by virtue of the fact that they have been prescribed for decades, have gained a history of safety and efficacy. Chloral hydrate was used for the short-term treatment of insomnia and as a sedative before minor medical or dental treatment. It was largely displaced in the mid-20th century by barbiturates and subsequently by benzodiazepines.
All meitnerium isotopes are extremely unstable (radioactive); in general, heavier isotopes are more stable than the lighter. The most stable known isotope, 278Mt (half-life 4.5 seconds), is also the heaviest known. The unconfirmed 282Mt is even heavier and seems to have a longer half-life, 67 seconds. With a half-life of 0.8 seconds, the next most stable known isotope is 270Mt. 276Mt and 274Mt have half-lives of 0.62 and 0.64 seconds respectively. 277Mt, created as the final decay product of 293Ts for the first time in 2012, was observed to undergo spontaneous fission, half-life 5 milliseconds. Preliminary data analysis considered the possibility that this fission is instead from 277Hs, for it also has a half-life of a few milliseconds, and could come from undetected electron capture somewhere in the decay chain. This possibility was later deemed very unlikely based on observed decay energies of 281Ds and 281Rg and the short half-life of 277Mt, although there is still some uncertainty of the assignment. Regardless, the rapid fission of 277Mt and 277Hs is strongly suggestive of a region of instability for superheavy nuclei with N = 168–170. The existence of this region, characterized by a decrease in fission barrier height between the deformed shell closure at N = 162 and spherical shell closure at N = 184, is consistent with theoretical models.
By the late 1930s, Thomas was embraced as the "poetic herald" for a group of English poets, the New Apocalyptics. Thomas refused to align himself with them and declined to sign their manifesto. He later stated that he believed they were "intellectual muckpots leaning on a theory". Despite this, many of the group, including Henry Treece, modelled their work on Thomas's. In the politically charged atmosphere of the 1930s Thomas's sympathies were very much with the radical left, to the point of his holding close links with the communists; he was also decidedly pacifist and anti-fascist. He was a supporter of the left-wing No More War Movement and boasted about participating in demonstrations against the British Union of Fascists. Bert Trick has provided an extensive account of an Oswald Mosley rally in the Plaza cinema in Swansea in July 1933 that he and Thomas attended.
The latter had expelled the Umayyads from the Hejaz and among the exiles to Syria was Marwan ibn al-Hakam, an Umayyad elder. Ubayd Allah persuaded Marwan, who was preparing to recognize Ibn al-Zubayr's sovereignty, to enter his candidacy as Mu'awiya II's successor. The Umayyads' principal Syrian allies, the Banu Kalb, had sought to maintain Umayyad rule and nominated Mu'awiya II's half-brother Khalid as caliph. However, the other pro-Umayyad Syrian tribes viewed Khalid as too young and inexperienced, and rallied around Marwan, who was ultimately chosen as caliph.
Sources: en.wikipedia.org
Because of this, despite Hua Tuo's reported success with general anesthesia, the practice of surgery in ancient China ended with his death. The name mafeisan combines ma (麻, meaning "cannabis, hemp, numbed or tingling"), fei (沸, meaning "boiling or bubbling"), and san (散, meaning "to break up or scatter", or "medicine in powder form"). Therefore, the word mafeisan probably means something like "cannabis boil powder". Many sinologists and scholars of traditional Chinese medicine have guessed at the composition of Hua Tuo's mafeisan powder, but the exact components still remain unclear. His formula is believed to have contained some combination of:
== Target == GsMTx-4 mainly targets mechanosensitive channels from the Piezo and TRP families, such as Piezo1 and TRPC6 which are generally bilayer tension-sensitive. This corresponds to the strong bilayer partitioning energy of GsMTx-4. It also targets a spectrum of voltage-dependent sodium channels (human Nav1.1- Nav1.7), human ERG channels (Kv11.1 and Kv11.2), and acetylcholine receptors.
On his retirement, Mahathir was named a Grand Commander of the Order of the Defender of the Realm, the highest honour in Malaysia, allowing him to adopt the title of "Tun". Under Mahathir's leadership, Malaysia was transformed into an industrialising nation. He pledged to leave politics "completely", rejecting an emeritus role in Abdullah's cabinet. Abdullah immediately made his mark as a quieter and less adversarial premier. With stronger religious credentials than Mahathir, he beat back PAS's surge in the 1999 election and lead the Barisan Nasional in the 2004 election to its biggest win ever, taking 199 of 219 parliamentary seats. On 23 October, Mingguan Malaysia, a Sunday edition of Utusan Malaysia, published an exclusive interview with Mahathir, marking his first since retiring as prime minister. After retiring, Mahathir maintained a busy schedule, engaging in various activities and speaking engagements both locally and internationally. In 2005, Russian president Vladimir Putin visited him at his private residence, where they held a four-hour meeting discussing Malaysia's economic transformation and development strategies. He emphasized the importance of staying active, stating, "Never retire. You have to work. When you work, it will keep you alive." His office at the Perdana Leadership Foundation and residence at the Mines Resort City, as well as expenses for meal allowances, escorts, bodyguards, a medical officer, and a special assistant during overseas trips, are funded by the government under the Member of Parliament (Remuneration) Act 1980 (Act 237).
== Causes == Few urethral diverticula are present at birth; the vast majority are acquired. Acquired urethral diverticula can be caused by trauma and/or infection. When the peri-urethral ducts become infected repeatedly, they can become blocked and eventually cause a diverticulum. They are usually found in the middle of the urethra or the end farthest from the bladder. Congenital urethral diverticula can arise from several embryological sources. These include defects in the primordial folds and remnants of Gartner's duct.
=== Valve Corporation v. Rothschild === In 2015, Display Technologies LLC, one of several IP-holding companies owned by Leigh Rothschild, sued Valve over patent infringement. While the suit was dismissed by January 2016, Valve shortly followed by acquiring licenses to twenty patents owned across Rothschild's firms. Around 2022, another Rothschild company, Patent Asset Management, began sending Valve demands to buy new licenses to two of the patents Valve already had licensed. Valve filed a lawsuit against the company in 2023 under Washington state's Patent Troll Protection and Consumer Protection Acts. In the months that followed, at least three lawsuits were filed in Texas by Rothschild's companies against Valve accusing Valve of additional patent infringement. Valve argued these suits were retaliatory to their Washington suit, and requested them to be dismissed. In February 2026, a jury found in Valve's favor on all counts.
Sources: en.wikipedia.org
In molecular biology, the amylin peptide family or calcitonin/CGRP/IAPP peptide family is a family of peptides, which includes the precursors of calcitonin/calcitonin gene-related peptide (CGRP), islet amyloid polypeptide (IAPP) and adrenomedullin. Calcitonin is a 32 amino acid polypeptide hormone that causes a rapid but short-lived drop in the level of calcium and phosphate in the blood, by promoting the incorporation of these ions in the bones, alpha type. Alternative splicing of the gene coding for calcitonin produces a distantly related peptide of 37 amino acids, called calcitonin gene-related peptide (CGRP), beta type. CGRP induces vasodilatation in a variety of vessels, including the coronary, cerebral and systemic vasculature. Its abundance in the CNS also points toward a neurotransmitter or neuromodulator role. Islet amyloid polypeptide (IAPP) (also known as diabetes-associated peptide (DAP), or amylin) is a peptide of 37 amino acids that selectively inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle, while not affecting adipocyte glucose metabolism. Structurally, IAPP is closely related to CGRP. Two conserved cysteines in the N-terminal of these peptides are known to be involved in a disulfide bond. The C-terminal amino acid of all three peptides is amidated.
Physicists were more accepting of Hahn's work, and he began attending a colloquium at the Physics Institute conducted by Heinrich Rubens. It was at one of these colloquia where, on 28 September 1907, he made the acquaintance of the Austrian physicist Lise Meitner. Almost the same age as himself, she was only the second woman to receive a doctorate from the University of Vienna, and had already published two papers on radioactivity. Rubens suggested her as a possible collaborator. So began the thirty-year collaboration and lifelong close friendship between the two scientists. In Montreal, Hahn had worked with physicists including at least one woman, Harriet Brooks, but it was difficult for Meitner at first. Women were not yet admitted to universities in Prussia. Meitner was allowed to work in the wood shop, which had its own external entrance, but could not enter the rest of the institute, including Hahn's laboratory space upstairs. If she wanted to go to the toilet, she had to use one at the restaurant down the street. The following year, women were admitted to universities, and Fischer lifted the restrictions and had women's toilets installed in the building.
=== United States === Beak trimming is legal in the United States, but there are some regulations: producers need to have a beak-trimming policy, it may not be employed to improve feed efficiency, but may be used to prevent cannibalism. Humane Society vice president Paul Shapiro stated that birds only resort to cannibalism when they are confined and have nothing to do. Reporters have stated that debeaking is only necessitated by farms' cramped and stressful condition. Industry groups have also stated that pecking behavior becomes worsened when hens are confined in close quarters.
As of 2019, the pathophysiology is largely not understood, although it is increasingly becoming accepted that calcium dysregulation plays a role. Calpain 3 is unique from other calpain proteases in that it is relatively specific to muscle. Calpain 3 is both a protease and a structural protein. As a protease, it cleaves proteins of the sarcomere and cytoskeleton, designating them to be degraded by proteasomes, a part of muscle remodeling. The structural role of calpain 3 is stabilization of the triad protein complexes. A triad protein complex plays a role converting electrical excitation into calcium release, and it is composed of two calcium channels, the ryanodine receptor (RYR1), and the dihydropyridine receptor (DHPR). With calpain 3 mutation, proteins typically found at the triad are reduced, including CaMKII (Ca2+/calmodulin-dependent protein kinase II). Decreased CaMKII activity impairs induction of slow oxidative gene expression, which in turn impairs genes involving the mitochondria and lipid metabolism.
According to the fluid mosaic model of S. J. Singer and G. L. Nicolson (1972), which replaced the earlier model of Davson and Danielli, biological membranes can be considered as a two-dimensional liquid in which lipid and protein molecules diffuse more or less easily. Although the lipid bilayers that form the basis of the membranes do indeed form two-dimensional liquids by themselves, the plasma membrane also contains a large quantity of proteins, which provide more structure. Examples of such structures are protein-protein complexes, pickets and fences formed by the actin-based cytoskeleton, and potentially lipid rafts.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.